Biosurgical Agents | Market Insights | Asia Pacific | 2021
The Asia Pacific biosurgical agents market is primarily driven by growing surgical procedure volumes due to expanding aging population and the rising prevalence of diseases associated with aging, obesity, diabetes, and cardiovascular disease, in addition to rising awareness of the clinical benefits of these products on surgical outcomes, and the introduction of new products with enhanced features and expanded indications. However, growing concerns over product cost and competition from local competitors will limit ASP growth in this market, thus hindering revenue expansion to some extent.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for biosurgical agents in the Asia Pacific region across a 10-year period.
